



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", #12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

11th August 2022

CIN: L85110KA1987PLC008739

To

Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

To

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI – 400 051.

Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Ref: Regulation 33, 36 & 42 of the SEBI (LODR) Regulations, 2015

With reference to the subject cited above, this is to intimate that the Board of Directors in its meeting held on 11th August 2022 which commenced at 02.30 p.m. and concluded at 6:30 p.m. have inter alia considered and approved: -

1. Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30 June 2022. A copy of Limited Review Report is also enclosed as **Annexure 1**.
2. Mr. Omprakash Inani (DIN No. 01301385) Chairman of the Company whose office is liable to retire by rotation at the ensuing Annual General Meeting, being eligible, offers himself for re-appointment.
3. Re-appointment of Mr. Sharath Reddy Kalakota (DIN No.03603460) as a Whole-Time Director subject to members approval in the ensuing Annual General Meeting.
4. Appointment of M/s. Bohara Bhandari Bung and Associates LLP, Chartered Accountants (Registration No. 008127S/S200013), as Statutory Auditors of the Company in place of M/s. Brahmayya & Co. for a term of 5 (Five) consecutive years subject to members approval in the ensuing Annual General Meeting.
5. Appointment of Dr. Anita Bandyopadhyay (DIN No: 08672071), as an Additional Women Independent Director of the Company to hold office upto the date of ensuing Annual General Meeting and recommending her appointment as a Women Independent Director for a period of 3 years subject to members approval in the ensuing Annual General Meeting. A brief profile of Dr. Anita Bandyopadhyay is enclosed as **Annexure 2**.



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", #12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

6. Appointment of Mr. Vishnukant C Bhutada (DIN 01243391) Managing Director of the Company as a ~~Managing Director of Shilpa Pharma Lifesciences Ltd, a wholly owned subsidiary of the company~~ on a remuneration subject to members approval in the ensuing Annual General Meeting.
7. Payment of remuneration to Mr. Hetal Madhukant Gandhi (DIN No.00106895), Independent Director in excess of remuneration paid to all Non-Executive Directors subject to members approval in the ensuing Annual General Meeting.
8. Approval of Minimum Remuneration payable to Non-Executive Directors subject to members approval in the ensuing Annual General Meeting.
9. Reconstituted the Committees of Board by inducting Mr. Arvind Vasudeva, Independent Director in the Audit Committee, Dr. Anita Bandyopadhyay, Additional Independent Director in the CSR Committee as Chairperson & as a member in Nomination & Remuneration Committee and Dr. Kamal K Sharma as a member in Stakeholders Relationship Committee & Risk Management Committee.
10. Notice of 35th Annual General Meeting, to be held on Wednesday, the 28th September 2022 at 11.30 a.m. (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.
11. The Register of Members will be closed from 21st September 2022 to 28th September 2022 (both days inclusive) for the purpose of dividend and the forthcoming Annual General Meeting.

This is for your information and necessary records.

For Shilpa Medicare Limited,

Ritu Tiwary
Company Secretary & Compliance Officer





Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

To the Board of Directors of **SHILPA MEDICARE LIMITED.**

1. We have reviewed the accompanying statement of unaudited standalone financial results of SHILPA MEDICARE LIMITED ("the Company") for the quarter ended 30th June, 2022 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **BRAHMAYYA & CO.**
Chartered Accountants
Firm's Regn No. 000513S



K. Shraavan
(K.SHRAVAN)

Partner

Membership No. 215798

UDIN: 22215798 AOVNHS4472

Place : Hyderabad

Date : 11.08.2022



Shilpa Medicare Limited
Incorporated in India

Shilpa Medicare Limited

Registered office: # 12-6-214/A-1, Hyderabad Road, Raichur- 584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com., Telephone -+91-8532-238494

CIN No. - L85110KA1987PLC008739

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. In Lakhs, except per equity share data)

Sl. No.	Particulars	Quarter ended			Previous year ended
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Continuing Operations:				
1	Income				
	Revenue from operations	6,083.42	7,287.29	10,526.07	35,695.18
	a) Net Sales/income from operations	4,369.61	5,221.82	10,382.77	32,609.03
	b) Service Income and License fees	1,713.82	2,065.47	143.31	3,086.15
	Other Income	1,262.82	1,033.56	963.77	4,086.20
	Total Income	7,346.24	8,320.85	11,489.84	39,781.38
2	Expenses				
	a) Cost of material consumed	1,546.69	1,845.78	2,629.05	7,518.73
	b) Purchase of stock-in-trade	94.20	-	414.85	677.73
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(689.15)	(788.92)	184.83	(317.86)
	d) Employee benefits expense	2,794.44	3,005.43	2,429.20	11,056.99
	e) Finance cost	265.87	173.15	248.99	905.37
	f) Depreciation and amortisation expenses	1,042.06	1,029.18	710.96	3,481.77
	g) Other expenses	1,887.13	3,379.55	3,609.10	14,590.97
	Total Expenses	6,941.23	8,644.17	10,226.98	37,913.70
3	Profit before tax and exceptional items (1-2)	405.01	(323.32)	1,262.86	1,867.68
4	Exceptional items- (Income)/Expenses (Pl refer note no: 03)	-	10.00	-	(880.90)
5	Profit Before Tax from continuing operations (3+4)	405.01	(333.32)	1,262.86	2,748.58
6	Tax Expense of continuing operations	19.57	(38.86)	377.83	732.75
	-Current tax	70.92	(58.24)	329.00	480.23
	-Deferred tax (Net of MAT credit)	(51.35)	19.38	48.83	252.52
7	Profit for the Period/year from continuing operations (5-6)	385.44	(294.46)	885.03	2,015.83
	Discontinued Operations:				
8	Profit/(loss) before tax for the period/year from discontinued operations (refer note no: 05)	8,148.77	5,544.58	1,883.03	16,540.71
9	Tax (expense)/credit of discontinued operations	(2273.73)	1,704.66	253.39	4,457.74
10	Profit for the period/year from discontinued operations (8-9)	10,422.50	3,839.92	1,629.64	12,082.97
11	Net profit for the period/year (7+10)	10,807.94	3,545.46	2,514.66	14,098.80
12	Other comprehensive income (OCI) from continuing operation				
	A. Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the defined benefit (liability)/asset	-	(122.95)	141.30	18.36
	B. Items that will be reclassified subsequently to profit or loss				
	Gain / (Loss) on derivative instrument (net)	-	-	16.81	22.73
	Total other comprehensive Income (net of tax)(A+B)	-	(122.95)	158.11	41.09
13	Other comprehensive income (OCI) from discontinuing operations				
	A. Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the defined benefit (liability)/asset	(144.96)	159.61	0.00	159.61
14	Total other comprehensive income/(expenses)for the period/year from continued operations	385.44	(417.41)	1,043.14	2,056.92
15	Total other comprehensive income/(expenses)for the period/year from discontinued operations	10,567.46	3,680.31	1,629.64	11,923.36
16	Total comprehensive income for the period / year (14+15)	10,952.90	3,262.90	2,672.77	13,980.28
17	Paid up equity share capital (par Value Rs.1/- each, fully paid)	868.02	868.02	815.27	868.02
18	Reserves i.e Other equity				205,698.77
19	Earnings per equity share (par value Rs.1/- each):	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Continuing Operations:				
	Basic (Rs.)	0.44	(0.34)	1.09	2.41
	Diluted (Rs.)	0.44	(0.34)	1.09	2.41
	Discontinued Operations:				
	Basic (Rs.)	12.01	4.42	2.00	14.46
	Diluted (Rs.)	12.01	4.42	2.00	14.46
	Total Operations:				
	Basic (Rs.)	12.45	4.08	3.08	16.87
	Diluted (Rs.)	12.45	4.08	3.08	16.87

Date: 11 August 2022
Place: Raichur



Omprakash Inani
Chairman
DIN 0130385



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of **SHILPA MEDICARE LIMITED**.

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SHILPA MEDICARE LIMITED (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and its share of the net loss after tax and total comprehensive loss of its associates and joint Ventures for the quarter ended 30th June, 2022 (the "Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the result of the following Subsidiaries/ Associates/Joint Ventures:
 - a. Koanaa Healthcare Limited, UK (Wholly owned subsidiary Company)
 - b. Koanaa Healthcare Limited, Austria (Wholly owned subsidiary Company)
 - c. Zatortia Holdings Limited (Wholly Owned Subsidiary Company)
 - d. Shilpa Therapeutics Private Limited (Wholly Owned Subsidiary Company)
 - e. INM Technologies Private Limited (Wholly Owned Subsidiary Company)
 - f. INM Nuvent Paints Private Limited (Step down Subsidiary Company)
 - g. Makindus, Inc (Subsidiary Company)
 - h. MAIA Pharmaceuticals, Inc (Associate Company)
 - i. Reva Medicare Private Limited (Joint Venture Company)
 - j. Reva Pharmachem Private Limited (Associate Company)
 - k. Shilpa Pharma Inc (Wholly owned subsidiary Company)





- l. Sravathi Advance Process Technologies Private Limited (Joint Venture Company)
 - m. Shilpa Biologicals Private Limited (Wholly Owned Subsidiary Company)
 - n. Shilpa Biocare Private Limited (Formerly known as "Shilpa Albumin Private Limited" - Wholly Owned Subsidiary Company)
 - o. Koanna Healthcare Canada Inc (Wholly owned subsidiary Company)
 - p. Shilpa Pharma Lifescience Limited (Formerly Known as Shilpa Corporate Holding Private Limited - Wholly owned subsidiary Company)
 - q. FTF Pharma Private Limited (Wholly owned subsidiary Company)
 - r. Auxilla Pharmaceuticals and Research LLP (Joint Venture)
 - s. Sravathi AI Technologies Private Limited (Joint Venture Company)
 - t. Indo Biotech SDN.BHD, Malaysia (Wholly Owned Subsidiary Company)
 - u. Koanna International FZ-LLC, Dubai (Wholly Owned Subsidiary Company)
 - v. Koanna Healthcare, Spain S.L (Wholly Owned Subsidiary Company)
 - w. Vegil Labs Private Limited (Wholly Owned Subsidiary Company)
 - x. Shilpa Lifesciences Private Ltd (Step down Subsidiary Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements of eight subsidiaries included in the consolidated unaudited financial results, whose interim financial statements reflects total revenue of Rs. 1364.97 lakhs, total net loss after tax of Rs (3768.56) lakhs and total comprehensive loss of Rs. (3767.48) lakhs for the quarter ended 30th June 2022, as considered in the consolidated unaudited financial results. The statement also includes the Group's share of net loss after tax of Rs. (73.30) lakhs and total comprehensive loss of Rs. (73.30) lakhs for the quarter ended 30th June 2022 as considered in the consolidated unaudited financial results, in respect of four joint ventures and one associate, whose interim financial statements have not been reviewed by us. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associate and Joint ventures is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.
7. The Statement includes the interim financial statements of nine subsidiaries which have not been reviewed, whose interim financial statements reflect total revenue of Rs. 838.20 lakhs, total net loss after tax of Rs. (296.16) lakhs and total comprehensive loss of Rs. (296.16) lakhs for the quarter ended 30th June 2022, as considered in the consolidated unaudited financial results. These interim financial statements have been approved and furnished to us by the Management and our conclusion on the statement, in so far as it relates to the affairs of these subsidiaries, is



Brahmayya & Co.,

CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

based solely on such interim financial statements. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

8. In case of one foreign associate interim financial statements for the quarter ended 30th June, 2022 are not concluded and have not been furnished to us by the Management, and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts included in respect of this associate is based solely on the information available for the period ended 31st December, 2022. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion on the statement is not modified in respect of the above matter.

for **BRAHMAYYA & CO.**
Chartered Accountants
Firm's Regn No. 000513S



K. Shrawan.
(K.SHRAVAN)

Partner

Membership No. 215798

UDIN: 22215798A0VNNI5072

Place : Hyderabad
Date : 11.08.2022



Accounting for
the distribution of financial results

Shilpa Medicare Limited

Registered office : # 12-6-214/A-1, Hyderabad Road, Raichur -584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com., Telephone --+91-8532-238494

CIN No. - L85110KA1987PLC008739

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. In Lakhs, except per equity share data)

Sl No.	Particulars	Quarter ended			Previous year ended
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	Revenue from operations	26,115.66	34,059.50	23,735.67	114,552.27
	a) Net Sales/income from operations	23,491.94	31,221.18	22,714.79	108,837.93
	b) Service Income and License fees	2,623.72	2,838.32	1,020.88	5,714.34
	Other Income	810.16	549.17	198.96	1,424.54
	Total Income	26,925.83	34,608.67	23,934.63	115,976.82
2	Expenses				
	a) Cost of material consumed	8,754.63	9,438.26	7,331.77	38,174.89
	b) Purchase of stock-in-trade	1,974.51	(78.72)	718.80	849.07
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(333.51)	1,996.64	(454.42)	(702.15)
	d) Employee benefits expense	7,285.79	7,342.62	5,785.46	26,448.65
	e) Finance cost	958.64	934.58	1,031.65	4,116.52
	f) Depreciation and amortisation expenses	2,241.98	2,234.28	1,763.32	7,980.19
	g) Other expenses	6,377.32	7,987.88	7,165.87	29,396.25
	Total Expenses	27,259.35	29,855.55	23,342.45	106,263.42
3	Profit before share of profit of joint venture and associates, exceptional items and tax (1)- (2)	(333.52)	4,753.13	592.18	9,713.40
4	Share of Profit / (loss) of Joint venture and associates, net of tax	(73.30)	(100.85)	(74.98)	(366.03)
5	Profit before tax and exceptional items (3-4)	(406.82)	4,652.28	517.20	9,347.36
6	Exceptional items- (Income)/Expenses (pl refer note no: 04)	-	11.80	-	(879.11)
7	Profit Before Tax (5+6)	(406.82)	4,640.48	517.20	10,226.47
8	Tax Expense	(641.12)	1,685.94	355.78	4,168.27
	-Current tax	1,494.43	944.60	557.13	3,404.31
	-Deferred tax (Net of MAT credit)	(2,135.55)	741.34	(201.35)	763.96
9	Profit for the Period / year before non-controlling interest (7)-(8)	234.30	2,954.54	161.42	6,058.20
10	Share of (loss)/profit attributable to non-controlling interest	(149.44)	(0.36)	(2.61)	(8.02)
11	Profit after taxes attributable to owners of the Parent Company for the period / year (9-10)	84.85	2,954.90	158.81	6,066.23
12	Other comprehensive income (OCI)				
	A. Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the defined benefit liability/asset Gain/(Loss) (net of tax)	146.04	(294.25)	139.26	(159.06)
	B. Items that will be reclassified subsequently to profit or loss				
	Gain / (Loss) on derivative instrument (net of tax)	-	-	16.81	22.73
	Total other comprehensive income(net of tax)(A+B)	146.04	(294.25)	156.07	(136.33)
13	Total comprehensive income for the period / year (11)+(12)	230.90	2,660.65	314.88	5,929.90
14	Paid up equity share capital (par Value Rs.1/- each, fully paid)	868.02	868.02	815.27	868.02
15	Reserves i.e other equity				181,351.46
16	Earnings per equity share (par value Rs.1/- each)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Basic (Rs.)	0.10	3.40	0.19	7.26
	Diluted (Rs.)	0.10	3.40	0.19	7.26



Notes:

- 1 The above unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2022 in respect of Shilpa Medicare Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on Aug 11, 2022. The above results have been subject to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- 2 These financial results have been prepared in accordance with Indian Accounting Standards('Ind-AS') notified under section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations,2015 and SEBI Circular dated July 5, 2016.
- 3 During the year ended March 31, 2022, the Company has recognised an exceptional income of Rs.890.90 Lakhs, realised on account of reduction of investment in one foreign subsidiary
- 4 During the year ended March 31, 2022, Seven investors infused Rs.29,751.00 Lakhs against preferential issue of equity shares of the Company which represents 6.08% shareholding of the Company. The consideration was received and equity shares were allotted on November 12, 2021. Calculation of EPS for the year ended March 31, 2022 is based on weighted average equity.
- 5 On 30 June,2022, The Company has completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company for a consideration of Rs. 48,630.00 lakhs .

Gain on disposal of assets/ liabilities amounting to Rs. 6,292.51 lakhs which is exceptional in nature has been disclosed under the discontinued operations.

Accordingly, results of API business for the quarter ended June 30, 2022 and comparatives for previous reporting periods has been disclosed as discontinued operations in the standalone results.

Particulars	INR in lakhs			
	Quarter ended			Year ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Amount	Amount	Amount	Amount
Total income from third parties	18,545.27	23,188.06	13,521.96	75,203.92
Inter company sales to units in continuing operations	1,221.47	2,611.76	1,578.60	7,724.56
Total income	19,766.74	25,799.82	15,100.56	82,928.48
Total expenses	17,910.49	20,255.24	13,217.53	66,387.78
Profit before tax and exception gain from discontinued operation	1,856.26	5,544.58	1,883.03	16,540.71
Exceptional Gain on Disposal of API Business.	6,292.51	-	-	-
Profit before tax from Discontinued Operations for the period	8,148.77	5,544.58	1,883.03	16,540.71
Tax Expense/ (Credit) of discontinued operations	(2,273.74)	1,704.66	253.39	4,457.74
Profit for the period from discontinued operations	10,422.51	3,839.92	1,629.64	12,082.97

There is Nil tax impact on the Exceptional Gain made from slump sale of one of its Business undertakings to its 100% wholly owned subsidiary U/S 47(iv) of the Income Tax Act, 1961

- 6 The Operating segment of the Company is " Pharmaceuticals", as the Chief Operating Decision Maker reviews business performance at an overall Company level as one segment . Therefore, segment reporting as per Ind-AS 108 is not applicable to the Company.
- 7 Prior period/year figures have been reclassified wherever required to conform to the classification of the current period/year. Also refer note 05 above.

Date: 11 August 2022

Place: Raichur



Omprakash Inani
Chairman
DIN 0130385

ANNEXURE 2

In view of the above and in pursuance to the requirements of Regulation 30 of (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular CIR/CFD/CMD/4/2015 dated 09 September 2015 following the information is given below:

Sub: Brief profile of Dr. Anita Bandyopadhyay – Independent Women Director of the Company

Name of the Independent Director	Dr. Anita Bandyopadhyay
Effective Date of Appointment	11 August 2022
Terms of Appointment	Appointed as additional Independent Women Director
Brief Profile	<p>Anita Bandyopadhyay holds Doctorate degree in Applied Psychology from Kolkata University and Executive MBA from SP Jain Institute of Management & Research, Mumbai. She is an acclaimed HR consultant with extensive expertise in Leadership Development, Talent Management, Performance Management, HR Processes and corporate succession planning.</p> <p>She has an amalgamation of strong conceptual knowledge with result-oriented application practice. She has serviced Pharmaceuticals, Glass Packaging, Education, Adhesives, Textile & Apparels Industries and has exposure to Manufacturing, Education, FMCG, Retail and B2B business sectors.</p>
Disclosure of relationships between directors (in case of appointment of a director)	Dr. Anita Bandyopadhyay is not related to any Director or Key Managerial Person of the Company and she does not hold any shares in the Company.
Directorship in Listed Companies	<p>1. Ami Organics Limited 2. Speciality Restaurants Limited</p> <p>Chairperson of Stakeholders Relationship Committee in Speciality Restaurants Limited and a Member of Nomination and Remuneration Committee in the aforesaid listed entities.</p>